Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation

Publication Date: 2017

Chairperson: Borja Ibanez & Stefan James

Acute coronary syndromes, Acute myocardial infarction, Antithrombotic therapy, Antithrombotics, Emergency medical system, Evidence, Fibrinolysis, Ischaemic heart disease, Primary percutaneous coronary intervention, Quality indicators, MINOCA, Reperfusion therapy, Risk assessment, Secondary prevention, ST-segment elevation

Pocket Guidelines on Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation

Link

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

Link

“Updates on the management of patients presenting with ST-segment elevation myocardial infarction (STEMI) should be based on sound evidence, derived from well-conducted clinical trials whenever possible, or motivated expert opinion when needed. It must be recognized that, even when excellent clinical trials have been undertaken, the results are open to interpretation and treatments may need to be adapted to take account of clinical circumstances and resources.

The present Task Force has made an important effort to be as aligned as possible with the other ESC Guidelines and consensus documents, including the simultaneously published update on dual antiplatelet therapy (DAPT), for consistency in the ESC Guidelines strategy. The levels of evidence and the strengths of recommendation of particular treatment options were weighed and graded according to pre-defined scales. Despite recommendations with a level of evidence being based on expert opinion, this Task Force decided to add references to guide the reader regarding data that were taken into consideration for these decisions in some cases.”